Rodolphe Anty1,2,3, Audrey Hastier4, Clémence M Canivet5,4,6, Stéphanie Patouraux5,6,7, Anne-Sophie Schneck5,4,6, Patricia Ferrari-Panaia7, Imed Ben-Amor4, Marie Christine Saint-Paul7, Jean Gugenheim5,4,6, Philippe Gual5,6, Antonio Iannelli5,4,6, Albert Tran5,4,6. 1. Institut National de la Santé et de la Recherche Médicale (INSERM), U1065, Team 8, "Hepatic Complications in Obesity", Nice, F-06204, Cedex 3, France. rodolphe.anty@laposte.net. 2. Pôle Référence Hépatite C, Hôpital de l'Archet 2, Centre Hospitalier Universitaire of Nice, 151, Route Saint-Antoine de Ginestière, BP 3079, F-06202, Nice, Cedex 3, France. rodolphe.anty@laposte.net. 3. Faculty of Medecine, University of Nice-Sophia-Antipolis, Nice, F-06107, Cedex 2, France. rodolphe.anty@laposte.net. 4. Pôle Référence Hépatite C, Hôpital de l'Archet 2, Centre Hospitalier Universitaire of Nice, 151, Route Saint-Antoine de Ginestière, BP 3079, F-06202, Nice, Cedex 3, France. 5. Institut National de la Santé et de la Recherche Médicale (INSERM), U1065, Team 8, "Hepatic Complications in Obesity", Nice, F-06204, Cedex 3, France. 6. Faculty of Medecine, University of Nice-Sophia-Antipolis, Nice, F-06107, Cedex 2, France. 7. Biological Centre, Centre Hospitalier Universitaire of Nice, Nice, F-06107, Cedex 2, France.
Abstract
BACKGROUND AND AIMS: A deficiency in vitamin D could be deleterious during chronic liver diseases. However, contradictory data have been published in patients with non-alcoholic fatty liver disease. The aim of the study was to compare the blood level of 25 hydroxy vitamin D (25-OH vitamin D) with the severity of liver lesions, in a large cohort of morbidly obese patients. PATIENTS AND METHOD: Three hundred ninety-eight morbidly obese patients had a liver biopsy. The non-alcoholic steatohepatitis (NASH) Clinical Research Network Scoring System Definition and Scores were used. 25-OH vitamin D was evaluated with a Diasorin®Elisa Kit. Logistic regression analyses were performed to obtain predictive factors of the severity of liver histology. RESULTS: 20.6 % of patients had NASH. The stage of fibrosis was F0 12.9 %, F1 57.36 %, F2 25.32 %, F3 (bridging fibrosis) 3.88 %, and F4 (cirrhosis) 0.52 %. The 25-OH vitamin D level inversely correlated to the NAS (r = 0.12 and p = 0.01) and to steatosis (r = 0.14 and p = 0.007); however, it was not associated with the presence of NASH. The level of vitamin D was significantly lower in patients with significant fibrosis compared to those without (15.9 (11.1-23.5) vs 19.6 (13.7-24.7) ng/ml, p = 0.02). There was an inverse correlation between the severity of fibrosis and the values of 25-OH vitamin D (r = 0.12 and p = 0.01). In a logistic regression analysis, no parameters were independently associated with the severity of fibrosis except the presence of steatohepatitis (1.94 (1.13-3.35) p = 0.017). CONCLUSION: Low levels of 25-OH vitamin D were not independently associated with liver damage in morbidly obese patients with non-alcoholic fatty liver diseases (NAFLD).
BACKGROUND AND AIMS: A deficiency in vitamin D could be deleterious during chronic liver diseases. However, contradictory data have been published in patients with non-alcoholic fatty liver disease. The aim of the study was to compare the blood level of 25 hydroxy vitamin D (25-OH vitamin D) with the severity of liver lesions, in a large cohort of morbidly obesepatients. PATIENTS AND METHOD: Three hundred ninety-eight morbidly obesepatients had a liver biopsy. The non-alcoholic steatohepatitis (NASH) Clinical Research Network Scoring System Definition and Scores were used. 25-OH vitamin D was evaluated with a Diasorin®Elisa Kit. Logistic regression analyses were performed to obtain predictive factors of the severity of liver histology. RESULTS: 20.6 % of patients had NASH. The stage of fibrosis was F0 12.9 %, F1 57.36 %, F2 25.32 %, F3 (bridging fibrosis) 3.88 %, and F4 (cirrhosis) 0.52 %. The 25-OH vitamin D level inversely correlated to the NAS (r = 0.12 and p = 0.01) and to steatosis (r = 0.14 and p = 0.007); however, it was not associated with the presence of NASH. The level of vitamin D was significantly lower in patients with significant fibrosis compared to those without (15.9 (11.1-23.5) vs 19.6 (13.7-24.7) ng/ml, p = 0.02). There was an inverse correlation between the severity of fibrosis and the values of 25-OH vitamin D (r = 0.12 and p = 0.01). In a logistic regression analysis, no parameters were independently associated with the severity of fibrosis except the presence of steatohepatitis (1.94 (1.13-3.35) p = 0.017). CONCLUSION: Low levels of 25-OH vitamin D were not independently associated with liver damage in morbidly obesepatients with non-alcoholic fatty liver diseases (NAFLD).
Authors: L Wamberg; T Christiansen; S K Paulsen; S Fisker; P Rask; L Rejnmark; B Richelsen; S B Pedersen Journal: Int J Obes (Lond) Date: 2012-07-17 Impact factor: 5.095
Authors: E M Stein; G Strain; N Sinha; D Ortiz; A Pomp; G Dakin; D J McMahon; R Bockman; S J Silverberg Journal: Clin Endocrinol (Oxf) Date: 2008-11-05 Impact factor: 3.478
Authors: Matthew T Kitson; Gregory J Dore; Jacob George; Peter Button; Geoffrey W McCaughan; Darrell H G Crawford; William Sievert; Martin D Weltman; Wendy S Cheng; Stuart K Roberts Journal: J Hepatol Date: 2012-11-23 Impact factor: 25.083
Authors: Ning Ding; Ruth T Yu; Nanthakumar Subramaniam; Mara H Sherman; Caroline Wilson; Renuka Rao; Mathias Leblanc; Sally Coulter; Mingxiao He; Christopher Scott; Sue L Lau; Annette R Atkins; Grant D Barish; Jenny E Gunton; Christopher Liddle; Michael Downes; Ronald M Evans Journal: Cell Date: 2013-04-25 Impact factor: 41.582
Authors: Yuval A Patel; Ricardo Henao; Cynthia A Moylan; Cynthia D Guy; Dawn L Piercy; Anna Mae Diehl; Manal F Abdelmalek Journal: Am J Gastroenterol Date: 2016-09-20 Impact factor: 10.864
Authors: Bryan Rudolph; Tyler Selig; Yingjie Li; Nadia Ovchinsky; Debora Kogan-Liberman; Mark C Liszewski; Terry Levin; Michelle Ewart; Qiang Liu; Shankar Viswanathan; Juan Lin; Xiaonan Xue; Robert D Burk; Howard D Strickler Journal: JPGN Rep Date: 2021-05
Authors: R Livadariu; D Timofte; A Trifan; R Danila; L Ionescu; A M Sîngeap; D Ciobanu Journal: Acta Endocrinol (Buchar) Date: 2018 Jan-Mar Impact factor: 0.877
Authors: Ilaria Barchetta; Maria Del Ben; Francesco Angelico; Michele Di Martino; Antonio Fraioli; Giuseppe La Torre; Rosella Saulle; Ludovica Perri; Sergio Morini; Claudio Tiberti; Laura Bertoccini; Flavia Agata Cimini; Francesca Panimolle; Carlo Catalano; Marco Giorgio Baroni; Maria Gisella Cavallo Journal: BMC Med Date: 2016-06-29 Impact factor: 8.775
Authors: A Drori; D Rotnemer-Golinkin; S Avni; A Drori; O Danay; D Levanon; J Tam; L Zolotarev; Y Ilan Journal: BMC Gastroenterol Date: 2017-11-28 Impact factor: 3.067